B. Riley lowered the firm’s price target on Varex Imaging (VREX) to $12 from $22 and keeps a Buy rating on the shares. Varex Imaging’s Q2 results were at the upper end of revenue guidance and above earnings guidance, the analyst tells investors in a research note. The firm notes that the 125% retaliatory tariffs have put the recovery in China on hold as Chinese customers have paused deliveries in anticipation of potential improvements in trade relations with the U.S. or potential exemptions for Varex products, which is expected to result in the loss of 2/3 of revenue from China in Q3 vs. Q2.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VREX:
